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Abstract 
 
In patients with chronic kidney disease (CKD) and heart failure (HF), volume 
overload is a major problem. Removal of fluid during the dialysis treatment is the 
cornerstone management in these conditions, but assessing the amount of volume 
that should be removed is a challenge since physical exam findings are not 
accurate. Ambulatory pulmonary artery (PA) pressure measurement is a promising 
tool in HF that potentially could be used as well in CKD population, monitoring 
volume status changes and allowing a prompt intervention such as increasing or 
decreasing the volume of ultrafiltration. We presented two cases of patients with 
CKD, HF and CardioMEMS. 
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Introduction 
 
Chronic kidney disease (CKD) affects 13.6 % of the US population1. A significant 
proportion of these patients progresses to end stage renal disease (ESRD) 
requiring renal replacement therapy or renal transplantation. Cardiovascular 
disease remains the most common cause of mortality in these patients2. 
Volume overload is a major problem in patients with kidney failure especially in 
those with an underlying heart disease3. It is not uncommon for dialysis patients to 
develop signs and symptoms of volume overload. Hence, removal of fluid during 
the dialysis treatment, also known as ultrafiltration, is the cornerstone of volume 
management in advanced-stage CKD4.  
 
Previous studies have revealed that excessive inter-dialytic weight gain is 
associated with adverse clinical outcomes5–9, finding it to be an independent 
predictor of all-cause and cardiovascular mortality in dialysis patients5. In addition, 
accumulating evidence shows that inter-dialytic weight gain is significantly 
associated with left ventricular hypertrophy and risk of cardiovascular mortality10,11. 
It could be helpful to prevent excessive inter-dialytic weight gain for improving 
clinical outcomes in incident dialysis patients12. 
 
A main challenge related to ultrafiltration is the assessment of the volume status 
and the required intra-dialytic fluid removal. Target weight in dialysis patients is the 
most commonly used method, and it is defined as the lowest tolerable body weight 
not associated with symptoms of hypovolemia13,14. However, in many 
circumstances it might be impossible to determine the ideal target weight based on 
clinical findings. Furthermore, this routine assessment has not contributed to 
reducing cardiovascular mortality in dialysis patients, which is ultimately one of the 
main long-term goals of renal replacement therapy.  
 
CardioMEMS system (Abbott, Abbott Park, IL) is a pressure sensor implanted into 
the pulmonary artery (PA) for remote monitoring of PA pressure in ambulatory 
patients. Pulmonary arterial pressure-guided heart failure (HF) management using 
CardioMEMS was tested in the CHAMPION trial (CardioMEMS Heart Sensor 
Allows Monitoring of Pressure to Improve Outcomes in NYHA (New York Heart 
Association) functional Class III Heart Failure Patients) and resulted in substantial 
reductions of hospitalizations for HF15. Testing of CardioMEMS in dialysis patients 
with HF seems logical, promising and has the potential of optimizing volume status 
and reducing cardiovascular complications. 
  
Herein we are reporting on two HF patients who had CardioMEMS and were later 
started on dialysis. Interestingly, one of them was switched from hemodialysis to 
peritoneal dialysis.  
 
Methods 
 
We retrospectively reviewed medical records of the two patients and collected the 
data on their demographics, clinical condition, medications, results of right heart 
catheterization, and echocardiographic reports. Also, we extracted the following 
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data from the hemodialysis records: pre-and post-dialytic weight, systemic blood 
pressure and heart rate, and the volume of fluid removed per session. 
We then collected CardioMEMS’s data, including PA systolic, diastolic, and mean 
pressure. Subsequent information on 60 CardioMEMS readings before the 
beginning of hemodialysis and equal number of readings on hemodialysis were 
collected. On the patient who was later switched to peritoneal dialysis, the 
readings of CardioMEMS while she was on peritoneal dialysis were collected as 
well. Mean PA pressures before and after the beginning of hemodialysis and on 
peritoneal dialysis were compared for each patient using Student’s t-test. 
 
Case 1. Heart Failure with Preserved Ejection Fraction 
 
65-year-old Caucasian female with history of type II diabetes, hypertension, CKD, 
hypothyroidism, hepatitis C, liver cirrhosis, had NYHA class III diastolic HF. 
Echocardiogram showed left ventricular ejection fraction >55%, normal right 
ventricular systolic function, right ventricular systolic pressure 40-50 mmHg, 
normal atrial and ventricular size (left ventricular end diastolic dimension 4.1 cm) 
and no valvular abnormalities. Cardiac catheterization demonstrated the following 
pressures: right atrium 11 mmHg, right ventricle 50/11 mmHg, PA 50/16 mmHg 
(mean 30 mmHg), pulmonary capillary wedge pressure 30 mmHg, cardiac output 
7.0 L/min and cardiac index 3.6 L/min/m2. CardioMEMS was implanted in 
November 2016. Her medications included metolazone 10 mg once a day, 
bumetanide 2mg twice a day, carvedilol 12.5 mg twice a day, isosorbide 
mononitrate 60 mg once a day, hydralazine 100 mg three times a day, cinacalcet 
30 mg once a day, insulin and levothyroxine. 
 
Patient had declining kidney function, and intermittent hemodialysis (HD) was 
initiated via a tunneled catheter in September 2018. Patient received 3.5 hour HD 
sessions regularly 3 times a week with an average blood flow rate of 400 
ml/minute and a fluid removal of 2 liters aiming a target weight of 78 kg. 
Patient’s vital signs and laboratory values are listed in Table 1. There was no any 
need to early terminate dialysis for hemodynamic instability or arrhythmias but she 
had complained of bad cramps with any attempt of taking take more fluid off. 
 
Table 1. Patient 1: Clinical parameters before and after dialysis session 
 
 Before HD session After HD session P 
 Mean ± SD Mean ± SD  
Weight, kg 78.2 ± 0.8 76.8 ± 0.6 <0.0001 
Systolic BP, mmHg 159.2 ± 30.2 149.1 ± 27.5 0.2 
Diastolic BP, mmHg 68.6 ± 11.5 64.5 ± 14.7 0.3 
Heart rate, beats per minute 60.2 ± 8.2 57.7 ± 4.7 0.2 
Net volume removed, L   1.45 ± 0.7   
BP- blood pressure 
HD – hemodialysis 
SD – standard deviation 
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Her dialysis adequacy measures were optimal (an average KT/V of 1.5, where K is 
the dialyzer clearance of urea, T stands for dialysis time and V is the volume of 
distribution of urea).  
 
The patient was switched to continuous cyclic peritoneal dialysis (PD) through a 
Tenckhoff PD catheter in January 2019 using four cycles with a total dialysate 
volume of 8800 ml over 8.5 hours. Her average KT/V was 2.0. Her PA pressure by 
CardioMEMS increased after initiation of the HD but decreased after PD was 
established (Figure 1, Table 2).  
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Case 2. Heart Failure with Reduced Ejection Fraction 
 
73-year-old Caucasian male with history of type II diabetes, hypertension, and 
CKD had NYHA class III systolic HF secondary to ischemic cardiomyopathy. 
Echocardiogram showed decreased left ventricular ejection fraction <25%, with a 
dilated left ventricle (end diastolic dimension of 6.4 cm), right ventricular systolic 
pressure 94 mmHg, and moderate mitral regurgitation. Right side heart 
catheterization demonstrated the following pressures: right atrium 11 mmHg, right 
ventricle 61/13 mmHg, PA 67/26 mmHg (mean 43 mmHg), pulmonary capillary 
wedge pressure 46 mmHg, cardiac output 5.7 L/min and cardiac index 2.8 
L/min/m2. CardioMEMS was implanted in October 2016.  
 
Patient had declining kidney function. A right upper arm arteriovenous fistula was 
placed, and intermittent HD was initiated in July 2018. Patient received 4 hours HD 
session regularly 3 times a week with an average blood flow rate of 400 ml/min 
and a fluid removal of 3.5-4.5 liters aiming a target weight of 89 kg (Table 3). 
There was no need to early terminate any of the dialysis sessions for 
hemodynamic instability or arrhythmia.   
 
 
 
His dialysis adequacy measures were optimal (an average KT/V of 1.7)  His 
medications included carvedilol 25mg twice a day, hydralazine 100 mg three times 
a day, Insulin and glimepiride. His PA pressures readings by CardioMEMS 
gradually declined after initiation of dialysis (Figure 2, Table 4).  
 
The volume of fluid removed per HD session was significantly greater in the 
second patient (3.2 ± 1.2 L vs 1.45 ± 0.7 L, P <0.0001). When we indexed the net 
volume removed for pre-dialysis weight, the difference persisted (0.003 ± 0.013 vs 
0.019 ± 0.009, P <0.0001). 
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Discussion  
 
Heart failure is a chronic condition, with the symptoms resulting from fluid retention 
due to inadequate cardiac output and elevated cardiac filling pressures3. Chronic 
volume overload in both HF and CKD results in left ventricular hypertrophy, 
dilatation and cardiac dysfunction, with or without decrease in left ventricular 
ejection fraction, increasing the risk of cardiovascular mortality16. Reversing 
hypervolemia remains the key management strategy in renal disease patients with 
HF3. In cases where hypervolemia is not controlled, dialysis could be used as an 
alternative. A previous prospective randomized study compared ultrafiltration and 
intravenous diuretics in patients hospitalized for acute decompensated HF and 
reported more fluid removal and decreased rehospitalization rates in those 
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undergoing ultrafiltration18. These results could be extrapolated to show the 
potential value of extracorporeal ultrafiltration as a treatment for HF in long-term 
dialysis patients. 
  
The CHAMPION Trial demonstrated the utility of PA pressure 
guided HF management strategy using a wireless implantable 
hemodynamic monitoring system. Patients managed with the addition to 
ambulatory hemodynamic monitoring were compared with patients on HF 
management based on practice guidelines only. CardioMEMS’ patients showed 
substantial reductions in hospital admissions for HF, irrespective of left ventricular 
pump function. This is probably because the PA pressure guided HF management 
facilitates timely recognition of incipient hypervolemia and appropriate modification 
of medical treatment.15   
 
We described two cases of patient with advanced CKD, HF and cardioMEMS, 
patients were identified to have elevated PA pressures even after receiving HD. A 
main challenge related to ultrafiltration in dialysis patients is the assessment of the 
required magnitude and frequency of fluid removal5. Dry weight is one of the most 
common methods used, but given that clinical findings are imprecise, this method 
cannot accurately predict the ultrafiltration volume12. Not uncommonly patients 
develop manifestations of hypovolemia during and after dialysis. It is well 
established that excessive volume removal is associated with repeated episodes 
of myocardial stunning developing regional fixed left ventricular dysfunction and 
worsening HF19. On the other hand, insufficient fluid removal is also associated 
with volume overload, deteriorating HF and worsening pulmonary hypertension.  
Another challenging situation is choosing the dialysis modality. The notion is 
continuos dialysis therapies are more hemodynamically tolerable and associated 
with less myocardial stunning. This is probably because of gentle fluid removal20, 
21.  
 
In our case number 1, the patient PA pressures, already elevated, worsened while 
on HD but significantly improved after she was switched to PD. In the two cases 
we presented, starting of dialysis clearly resulted in change of their PA pressures. 
In the first case of HF with preserved ejection fraction and small left ventricle, 
pulmonary pressures significantly increased. In the second case of HF with 
reduced ejection fraction and enlarged left ventricle, PA pressures decreased. 
In non-dialysis patients with HF, volume status is primarily controlled with loop 
diuretics, and the effect is dose-dependent.  In HD, fixed volume of fluid is 
removed three times a week. In the first patient, the amount of fluid removal could 
not be increased on HD because she experienced symptoms of hypovolemia. In 
HF with preserved ejection fraction small changes in intravascular volume produce 
marked changes in intra-cardiac pressures22, possibly due to small and non-
compliant left ventricle.  
 
On the other hand, the patient with large ventricle tolerated higher volumes of fluid 
removed per HD session. The amount of fluid removal per HD session was lower 
in the first compared to the second patient, both in absolute values and indexed for 
body weight. The first patient’s hemodynamics much improved on PD with more 
gentle and gradual fluid removal. This might be because PD allows more time for 
the heart to accommodate intravascular volume changes as it is more slow/chronic 
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dialysis therapy compared to HD. Of note, hemodynamic response to dialysis in 
these two patients demonstrates that approach to chronic renal replacement 
therapy may differ in patients with HF with reduced and preserved ejection 
fraction. 
 
Conclusions 
   
Management of fluid status is a significant challenge in dialysis patients with HF. 
Up to date there is no clear recommendation of how to determine the appropriate 
amount of ultrafiltration. Remote ambulatory monitoring of PA pressures helps in 
guiding the amount of fluid removal in this patient population. Testing 
CardioMEMS in this clinical setting is promising since it accurately predicts the 
volume status. Ambulatory monitoring of volume status may help with decision 
making on the modality of dialysis. More studies are needed in order to establish 
the utility of using this device in improving clinical outcome. 
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